Pargyline Hydrochloride | CAS#306-07-0 | MAO inhibitor

Pargyline Hydrochloride
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318456

CAS#: 306-07-0

Description: Pargyline hydrochloride is a monoamine oxidase inhibitor with antihypertensive properties. Pargyline selectively inhibits MAO type B, an enzyme catalyzing the oxidative deamination and inactivation of certain catecholamines, such as norepinephrine and dopamine, within the presynaptic nerve terminals. By inhibiting the metabolism of these biogenic amines in the brain, pargyline increases their concentration and binding to postsynaptic receptors.

Chemical Structure

Pargyline Hydrochloride

CAS# 306-07-0

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 318456
Name: Pargyline Hydrochloride
CAS#: 306-07-0
Chemical Formula: C11H14ClN
Exact Mass: 0.00
Molecular Weight: 195.690
Elemental Analysis: C, 67.51; H, 7.21; Cl, 18.12; N, 7.16

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 350
200mg	USD 650
500mg	USD 950
1g	USD 1450
2g	USD 2250
5g	USD 2950
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Pargyline Hydrochloride; N-benzyl-N-methylprop-2-yn-1-amine hydrochloride; Eutonyl-ten; N-Methyl-N-propargylbenzylamine hydrochloride; Pargyline HCl; Pargyline;

IUPAC/Chemical Name: N-benzyl-N-methylprop-2-yn-1-amine;hydrochloride

InChi Key: BCXCABRDBBWWGY-UHFFFAOYSA-N

InChi Code: InChI=1S/C11H13N.ClH/c1-3-9-12(2)10-11-7-5-4-6-8-11;/h1,4-8H,9-10H2,2H3;1H

SMILES Code: CN(CC#C)CC1=CC=CC=C1.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B.
In vitro activity:	The purpose of this study was to investigate the effects of the MAO inhibitors, pargyline and tranylcypromine on cell survival in human prostate carcinoma (LNCaP-LN3) cells. The proliferation of cells exposed to pargyline decreased in a dose- and time-dependent manner, while tranylcypromine-treated cells showed the opposite results. Treatment with pargyline significantly induced cell cycle arrest at the G1 phase compared to the control and tranylcypromine-treated cells. In addition, pargyline induced an increase in the cell death rate by promoting apoptosis; however, tranylcypromine had no effect on LNCaP-LN3 cells. Reference: Oncol Rep. 2013 Oct;30(4):1587-92. https://pubmed.ncbi.nlm.nih.gov/23900512/
In vivo activity:	SCID mice were injected subcutaneously with LNCap cells. Pargyline was given intraperitoneally or not after castration (implemented with Bilateral orchidectomy), then PSA levels in serum and tumor were determined to assess time to androgen-independent progression. The results showed that LSD1 expression was up-regulated when PCa progressed to Castration Resistant Prostate Cancer (CRPC). Pargyline reduced LNCap cells migration and invasion ability, and inhibited the process of EMT by up-regulating expression of E-cadherin, and down-regulating expressions of N-cadherin and Vimentin in vitro and in vivo. Although, Pargyline did not change the level of AR, it reduced PSA expression both in vitro and in vivo. Furthermore, Pargyline delayed prostate cancer transition from androgen-dependent to androgen-independent state (CRPC). Reference: Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. https://pubmed.ncbi.nlm.nih.gov/26435505/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	20.0	102.20
	DMSO	30.3	155.01
	Ethanol	34.5	176.30
	PBS (pH 7.2)	5.0	25.55
	Water	69.5	355.15

Preparing Stock Solutions

The following data is based on the product molecular weight 195.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Lee HT, Choi MR, Doh MS, Jung KH, Chai YG. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92. doi: 10.3892/or.2013.2635. Epub 2013 Jul 24. PMID: 23900512; PMCID: PMC3810355. 2. Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. doi: 10.1016/j.bbrc.2015.09.164. Epub 2015 Oct 3. PMID: 26435505. 3. Chaaya R, Alfarano C, Guilbeau-Frugier C, Coatrieux C, Kesteman AS, Parini A, Fares N, Gue M, Schanstra JP, Bascands JL. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrol Dial Transplant. 2011 Feb;26(2):489-98. doi: 10.1093/ndt/gfq445. Epub 2010 Jul 28. PMID: 20667995.
In vitro protocol:	1. Lee HT, Choi MR, Doh MS, Jung KH, Chai YG. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30(4):1587-92. doi: 10.3892/or.2013.2635. Epub 2013 Jul 24. PMID: 23900512; PMCID: PMC3810355.
In vivo protocol:	1. Wang M, Liu X, Guo J, Weng X, Jiang G, Wang Z, He L. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Biochem Biophys Res Commun. 2015 Nov 13;467(2):310-5. doi: 10.1016/j.bbrc.2015.09.164. Epub 2015 Oct 3. PMID: 26435505. 2. Chaaya R, Alfarano C, Guilbeau-Frugier C, Coatrieux C, Kesteman AS, Parini A, Fares N, Gue M, Schanstra JP, Bascands JL. Pargyline reduces renal damage associated with ischaemia-reperfusion and cyclosporin. Nephrol Dial Transplant. 2011 Feb;26(2):489-98. doi: 10.1093/ndt/gfq445. Epub 2010 Jul 28. PMID: 20667995.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Lowe MC. Hepatotoxicity of pargyline hydrochloride. Proc West Pharmacol Soc.
1978;21:215. PubMed PMID: 693498.

2: Fletcher FW. A unique antihypertensive combination--pargyline hydrochloride
and methyclothiazide: a controlled study of twenty-five patients over a
nine-month period. Curr Ther Res Clin Exp. 1968 Aug;10(8):394-8. PubMed PMID:
4970052.

3: Cantalapiedra Alsedo JL, Del Pozo P. [Clinical experience using pargyline
hydrochloride in the treatment of arterial hypertension]. Rev Clin Esp. 1968 Apr
15;109(1):57-62. Spanish. PubMed PMID: 5738826.

4: Goodsell EB, Krause RA. The effect of prolonged administration of pargyline
hydrochloride (a non-hydrazine monoamine oxidase inhibitor) on glucose
utilization in dogs. Arch Int Pharmacodyn Ther. 1968 Feb;171(2):475-90. PubMed
PMID: 5685843.

5: Lipkin D, Kushnick T. Pargyline hydrochloride poisoning in a child. JAMA. 1967
Jul 3;201(1):135-6. PubMed PMID: 6071697.

6: Hergueta G, García de Guadiana. [Clinical evaluation of pargyline
hydrochloride in the therapy of arterial hypertension]. Rev Esp Cardiol. 1967
Jul;20(3):387-95. Spanish. PubMed PMID: 5613891.

7: Waldmann EB, Nickas G. Pargyline hydrochloride combined with methyclothiazide
in the treatment of hypertension. Ariz Med. 1967 Apr;24(4):343-6. PubMed PMID:
6046398.

8: Sannerstedt R. Hemodynamic effects of pargyline hydrochloride at rest and
during exercise in hypertension. Acta Med Scand. 1967 Jan;181(6):699-706. PubMed
PMID: 4951468.

9: Tcherdakoff P, Leroux-Robert C, Milliez P. [Treatment of arterial hypertension
with pargyline hydrochloride]. Sem Ther. 1966 Dec;42(10):582-6. French. PubMed
PMID: 5996656.

10: Hamm HJ. Pargyline hydrochloride combined with methyclothiazide in the
treatment of essential hypertension. Curr Ther Res Clin Exp. 1966
Aug;8(8):378-83. PubMed PMID: 4958153.

11: Carmichael DB. Aged cheese, pargyline hydrochloride, and paradoxical
hypertension. J Lancet. 1966 May;86(5):235-8. PubMed PMID: 5910166.

12: Breall WS. Treatment of hypertension with a combination of pargyline
hydrochloride and methyclothiazide. J Am Geriatr Soc. 1966 Jan;14(1):85-7. PubMed
PMID: 5901935.

13: Hechart BB, Garimaldi JC, Claria Olmedo RA. [Antihypertensive effect of
pargyline hydrochloride]. Rev Sanid Milit Argent. 1965 Jul-Dec;64(3):140-7.
Spanish. PubMed PMID: 5875067.

14: VAN DYNE JR. PARGYLINE HYDROCHLORIDE IN TREATMENT OF RESISTANT HYPERTENSION.
N Y State J Med. 1965 Jun 15;65:1672-5. PubMed PMID: 14302202.

15: RANGLE RV. THE ANTIHYPERTENSIVE AND HYPOGLYCEMIC EFFECTS OF PARGYLINE
HYDROCHLORIDE. Angiology. 1965 Jun;16:351-4. PubMed PMID: 14294431.

16: BARTOLI AJ. A CLINICAL STUDY OF PARGYLINE HYDROCHLORIDE. West Med Med J West.
1965 Apr;6:110-4 PASSIM. PubMed PMID: 14318405.

17: HUTCHISON JC, KINLAW WB, KRAVITZ B. PARGYLINE HYDROCHLORIDE AND AMINE
HYPERTENSION. Angiology. 1965 Apr;16:187-202. PubMed PMID: 14275865.

18: POLLACK PJ. PARGYLINE HYDROCHLORIDE AND METHYCLOTHIAZIDE COMBINED IN THE
TREATMENT OF HYPERTENSION. Curr Ther Res Clin Exp. 1965 Jan;7:10-8. PubMed PMID:
14246362.

19: Borrero J, Martínez G, Cárdenas C, Restrepo D, Escobar A. [Clinical
evaluation of the hypotensive effect of pargyline hydrochloride and
methyclothiazide]. Antioquia Med. 1965;15(3):159-73. Spanish. PubMed PMID:
5318105.

20: SAWYER NJ, MILLS DM, TROOP RC. EURONYL: PARGYLINE HYDROCHLORIDE. Curr Ther
Res Clin Exp. 1964 Aug;6:538-48. PubMed PMID: 14202214.

Your view history

Pargyline Hydrochloride featured